CytoMed Therapeutics

GDTCPhase 1

CytoMed Therapeutics is focused on translating innovative immunology research into transformative cancer treatments, primarily through its two core platforms: allogeneic γδ T cell therapies and CAR-engineered γδ T cells. The company's lead candidate, CTM-N2D, is an off-the-shelf, donor-derived γδ T cell product in Phase 1 development for various solid tumors. With a NASDAQ listing and a strategic base in Singapore's biotech hub, CytoMed aims to address significant unmet needs in oncology by developing safer and more accessible cell therapies.

Market Cap

$12.9M

Employees

11-50

Focus

Biotech

GDTC · Stock Price

USD 1.102.90 (-72.50%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platforms for developing off-the-shelf allogeneic immunotherapies using gamma-delta T cells (γδ T cells), both in unmodified form and engineered with Chimeric Antigen Receptors (CARs).

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2...	Cancer	Phase 1
human Mesenchymal Stem Cell (MSC) infusion therapy	Aging Well	Phase 1
Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Ga...	Colorectal Cancer	Phase 1

Funding History

Total raised: $18.5M

IPO$12MUndisclosedFeb 8, 2023

Series A$5MUndisclosedMar 15, 2021

Seed$1.5MUndisclosedJun 15, 2020

Opportunities

The company is positioned in the high-growth allogeneic cell therapy market, with a platform uniquely suited for solid tumors—a vast area of unmet need.

Successful clinical data could lead to strategic partnerships or acquisition interest from larger oncology-focused pharmaceutical companies seeking next-generation immunotherapy assets.

Risk Factors

CytoMed faces high clinical development risk with its early-stage pipeline, financial risk due to its pre-revenue status and need for future capital, and intense competition in the cell therapy space.

The novel scientific approach using γδ T cells, while promising, remains unproven in late-stage trials.

Competitive Landscape

CytoMed competes with other γδ T cell therapy developers (e.g., Adicet Bio, TC Biopharm) and allogeneic CAR-T companies (e.g., Allogene Therapeutics). Its key differentiation is the use of donor-derived γδ T cells, which may offer a superior safety profile for off-the-shelf therapies and enhanced potential against solid tumors compared to conventional αβ T cell approaches.